Pharmacologic deficiency in the Women's Health Initiative study

Journal of Reproductive Medicine for the Obstetrician and Gynecologist

Volumn 48, Issue 6, 2003, Pages 485-486

  Stanczyk, Frank Z ^a   Chaikittisilpa, Sukanya ^a   Roy, Subir ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Cardiovascular disease; Hormone replacement therapy; Women's Health Initiative

Indexed keywords

CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE;

ADULT; AGED; BODY COMPOSITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG INDUCED DISEASE; FEMALE; HEALTH STATUS; HORMONAL THERAPY; HUMAN; HUMAN EXPERIMENT; KIDNEY FUNCTION; LETTER; LIVER FUNCTION; MENOPAUSAL SYNDROME; NORMAL HUMAN; PATIENT SATISFACTION; PRIORITY JOURNAL; TREATMENT PLANNING;

AGE FACTORS; AGED; AGING; BODY COMPOSITION; DRUG COMBINATIONS; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; WOMEN'S HEALTH;

EID: 0037973297     PISSN: 00247758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (19)

1. Writing Group for the Women's Health Initiative Investigators: Risk and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-333
2. The Women's Health Initiative Study Group: Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials 1998;19:61-109
3. Greenblatt DJ, Abernethy DR, Shader RI: Pharmacokinetic aspects of drug therapy in the elderly. Ther Drug Monit 1996;8:249-255
4. Montamat S, Cusack B, Vestal R: Management of drug therapy in the elderly. N Engl J Med 1989;321:303-309
5. Platt D (editor): Drugs and Aging. Berlin, Springer, 1986
6. Durnas C, Loi CM, Cusack BJ: Hepatic drug metabolism and aging. Clin Pharmacokinet 1990;19:359-389
7. Lindeman RD: Changes in renal function with aging: Implications for treatment. Drugs Aging 1992;2:423-431
8. Wynne H, Cope L, Mutch E, et al: The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology 1989;9:297-301
9. Tsujimoto G, Hashimoto K, Hoffman BB: Pharmacokinetic and pharmacodynamic principles of drug therapy in old age: Part 1. Int J Clin Pharmacol Ther Toxicol 1989;27:13-26
10. Sotaniemi EA, Arranto AJ, Pelkonen O, et al: Age and cytochrome P450-linked drug metabolism in humans: An analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Therapeut 1997;61:331-339
11. Novak LP: Aging, total body potassium, fat free mass and cell mass in males and females between the ages 18 and 85 years. J Gerontol 1972;27:438-443
12. Hollister LE: General principles of treating the elderly with drugs. In Clinical Pharmacology and the Aged Patient. Edited by L Jarvic. New York, Raven Press, 1981, pp 1-9
13. Forbes GB, Reina JC: Adult lean body mass declines with age: Some longitudinal observations. Metabolism 1970;19:653-663
14. Mühlberg W, Platt D: Age-dependent changes of the kidneys: Pharmacological implications. Gerontology 1999;45:243-253
15. Zeeh J, Platt D: The aging liver. Gerontology. 2002;48:121-127
16. Greenblatt DJ, Divoll M, Abernethy DR, et al: Physiologic changes in old age: Relation to altered drug disposition. J Am Geriatr Soc 1982;30:S6-S10
17. Tregaskis BF, Stevenson IH: Pharmacokinetics in old age. Br Med Bull 1990;46:9-21
18. Stevenson JC: Cardiovascular effects of estrogens. J Steroid Biochem Mol Biol 2000;74:387-393
19. Sitruk-Ware R: Progestins and cardiovascular risk markers. Steroids 2000;65:651-658